Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00578266
Other study ID # 06-006216
Secondary ID
Status Completed
Phase Phase 1
First received December 17, 2007
Last updated March 23, 2017
Start date February 2007
Est. completion date August 16, 2016

Study information

Verified date March 2017
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

For patients with severe aplastic anemia (SAA) who have failed to respond to immunosuppressive therapy and lack an HLA identical family member, our objectives are to make an initial assessment of the safety and efficacy of allogenic stem cell transplantation from either a matched unrelated donor or a mismatched reacted donor using the conditioning regimen of Cytoxan, reduced total body irradiation (TBI) and Campath IH. The principle measures of safety and efficacy will be :

1. Patient survival probability at 100 days, 1 year and 2 years.

2. Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and chronic GVHD within 6 months and 2 years.

3. Engraftment at 6 months, 1 year and 2 years


Description:

The objective of this trial is to make an initial assessment for this new treatment regimen and to show it is equal or superior to the current standard practice. With this initial assessment be hope to gain information suggesting further study of this regimen or discontinuation of this regimen before exposing large numbers of patients to this new treatment option. We also will gain experience with this new regimen giving insights as to possible modifications in dosing and monitoring and selection of patients for future treatment in case of positive results. For this initial study we plan to enroll up to 24 patients.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date August 16, 2016
Est. primary completion date August 16, 2016
Accepts healthy volunteers No
Gender All
Age group N/A to 60 Years
Eligibility Inclusion Criteria:

- Diagnosis of SAA based on bone marrow aspirate and biopsy results. Failure to respond to immunosuppressive therapy and/or lack of an HLA identical family member.

- A 10/10 or 9/10 HLA matched unrelated donor or a 9/10 matched related donor available after high resolution typing.

Exclusion Criteria:

- Patients with Aplastic anemia and active infection must be treated to maximally resolve this problem before beginning the conditioning regimen.

- HIV seropositive patients

- Patients who have clonal cytogenetic abnormalities or a myelodysplastic syndrome.

- Patient greater than 60 years of age.

- Women who are pregnant or nursing.

- Patients with active hepatitis

- Patients with severe cardiac dysfunction defined as shortening fraction <25%.

- Patients with severe renal dysfunction defined as creatinine clearance <40ml/mim/1.73m2.

- Patient with severe pulmonary dysfunction with FEV1, FVC and DLCO 40% of predicted or 3 SD below normal.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cyclophosphamide,Campath IH and TBI
DAY 5 TREATMENT 6 5 CYTOXAN 50 mg/kg WITH MESNA 5 CYTOXAN 50 mg/kg WITH MESNA; 4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg 3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH; 2 TBI; CAMPATH; TACROLIMUS 1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 1. Engraftment at 6 months, 1 year and 2 years 2.Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and chronic GVHD within 6 months and 2 years 2 years
Secondary Patient survival probability at 100 days, 1 year and 2 years. 2 years
See also
  Status Clinical Trial Phase
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT00229619 - Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Phase 2
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Completed NCT00005682 - Aplastic Anemia Epidemiology: Incidence and Case-control N/A
Completed NCT00692926 - Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells Phase 1
Completed NCT00244010 - Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias N/A
Recruiting NCT00399971 - Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia Phase 1/Phase 2
Completed NCT00683046 - T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Phase 2
Completed NCT00922883 - A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients Phase 2
Recruiting NCT00319878 - Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia Phase 1/Phase 2
Completed NCT00061763 - Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias Phase 2
Completed NCT00144729 - Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor Phase 1/Phase 2
Completed NCT00000597 - Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders Phase 3
Recruiting NCT02773225 - Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA) Phase 2/Phase 3
Terminated NCT03733249 - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Phase 1/Phase 2
Active, not recruiting NCT00737685 - Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA) Phase 2
Completed NCT00326417 - Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Phase 1/Phase 2
Completed NCT00618969 - Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors Phase 2